Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1hindole5-carbonyl]-amino}-3-(phenylpyridin-2-y l-amino)-propionic acid as an ikB kinase inhibitor

Details for Australian Patent Application No. 2005245834 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors Aldous, David J.; Ritzeler, Olaf; Cox, Paul Joseph; Haddad, El-Bdaoui

Agent Watermark

Pub. Number AU-A-2005245834

PCT Pub. Number WO2005/113544

Priority 60/570,146 12.05.04 US

Filing date 11 May 2005

Wipo publication date 1 December 2005

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

30 November 2006 PCT application entered the National Phase

  PCT publication WO2005/113544 Priority application(s): WO2005/113544

4 June 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005245846-Industrial roll with piezoelectric sensors for detecting pressure

2005245833-Polyetheralkanolamine dispersants